T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced three new
Board of Director appointments. The three new directors will add
significant clinical and commercialization experience and expand
board diversity, coupled with a strong understanding of the
Company’s customer base.
The new appointments include: Thierry Bernard, Chief Executive
Officer, QIAGEN; Dr. Ninfa Saunders, President and Chief Executive
Officer, Navicent Health; and Robin Toft, Founder and Chief
Executive Officer, Toft Group, a ZRG company.
“We are thrilled to add to our Board three individuals whose
commercial expertise and combined background in molecular
diagnostics, clinical care, and life science leadership will bring
invaluable perspective and insight to our business, helping us to
achieve our goals of accelerating our sales, improving our
operations, and advancing our pipeline,” said John Sperzel,
President and Chief Executive Officer, T2 Biosystems. “Our
commitment to developing innovative technology that helps save
lives and improve patient outcomes remains steadfast, and adding
these three industry leaders will bolster our efforts to accomplish
that in the coming months and years.”
Thierry Bernard is the CEO at QIAGEN. Mr. Bernard joined QIAGEN
in February 2015 to lead QIAGEN’s growing presence in molecular
diagnostics. Mr. Bernard previously held multiple roles at
bioMerieux for fifteen years, most recently as Corporate Vice
President, Global Commercial Operations, Investor Relations and the
Greater China Region. Prior to joining bioMerieux, he served in
management roles in multiple international environments. Mr.
Bernard is a member of the Board of Directors of First Light
Biosciences. He has earned degrees from Sciences Po (Paris),
Harvard Business School, London School of Economics and the College
of Europe, and is a member of French Foreign Trade Advisors.
Dr. Ninfa M. Saunders, FACHE, is the President and CEO of
Navicent Health, the second largest hospital in Georgia and a
tertiary regional teaching medical center. Dr. Saunders has more
than 45 years of hospital administrative and clinical experience,
and prior to her current role, served as the President and COO of
Virtua Health, the largest health system in southern New Jersey.
Dr. Saunders was recognized by Modern Healthcare as one of 2019’s
Top 25 Women Leaders in the U.S. and was twice named one of the
“Most Influential Women of the Mid-Market” in the U.S. by CEO
Corporation. Dr. Saunders serves on the boards of the Georgia
Hospital Association and the American Hospital Association, where
she is the past chair for the Institute for Diversity. Dr. Saunders
completed her Doctorate in Healthcare Administration at the Medical
University of South Carolina, earned a Master’s of Business
Administration from Emory University, and a Master of Science in
Nursing from Rutgers University.
Robin Toft is the founder and CEO of Toft Group, a ZRG company,
where she combines a deep inside knowledge of the life science
industry with a passion for building game-changing management
teams. Ms. Toft has placed hundreds of executives at innovation-led
life science companies. A champion of diverse executive teams, she
has built a reputation for recruiting women and minorities into
C-level and board of director roles. Prior to founding Toft Group
in 2010, Ms. Toft served 20+ years as a biotech executive, most
recently as Senior Vice President, Commercial Operations at Roche
Molecular Diagnostics. In the 2020 American Business Awards, Ms.
Toft received three Gold awards for Lifetime Achievement, Maverick
of the Year and Woman of the Year. She currently serves on
The Clearity Foundation board for ovarian cancer care, and is
Chairman of LEAD San Diego, dedicated to developing civically
engaged leaders. Ms. Toft earned a Bachelor of Science from
Michigan State University.
Along with these additions, the Company announced the departure
of three long-standing board members: Michael Cima, Ph.D., Adrian
M. Jones, and Stanley Lapidus.
“We are profoundly grateful for the passion, ingenuity and
leadership exhibited by the departing board members over the past
several years,” said John McDonough, Chairman of the Board of
Directors, T2 Biosystems. “Their collective contributions have made
a significant and lasting impact on the Company, for which we will
remain forever grateful.”
The new board members will join the following existing board
members:
- John Sperzel, President and CEO, T2 Biosystems
- John McDonough, Chairman of the Board, T2 Biosystems
- John W. Cumming, Former Chairman and CEO, Hologic
- David Elsbree, Former Senior Partner, Deloitte &
Touche
- Seymour Liebman, Executive Vice President, Chief Administrative
Officer and General Counsel of Canon U.S.A, Inc.; Senior Managing
Executive Officer of Canon Inc., Japan; and Vice Chairman, Canon
Solutions America, Inc.
About T2 Biosystems T2 Biosystems, a
leader in the rapid detection of sepsis-causing pathogens, is
dedicated to improving patient care and reducing the cost of care
by helping clinicians effectively treat patients faster than ever
before. T2 Biosystems’ products include the T2Dx® Instrument,
T2Candida® Panel, the T2Bacteria® Panel, and the
T2Resistance™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2Cauris™ Panel,
T2SARS-CoV-2™ Panel, and T2Lyme™ Panel, as well as
additional products for the detection of bacterial and fungal
pathogens and associated antimicrobial resistance markers, as well
as biothreat pathogens.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding growth in the
Company’s sales, improvement in operations, and pipeline
advancement, as well as statements that include the words “expect,”
“intend,” “plan,” “believe,” “project,” “forecast,” “estimate,”
“may,” “should,” “anticipate,” and similar statements of a future
or forward looking nature. These forward-looking statements are
based on management's current expectations. These statements are
neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements, including,
but not limited to, (i) any inability to (a) realize anticipated
benefits from commitments, contracts or products; (b) successfully
execute strategic priorities; (c) bring products to market; (d)
expand product usage or adoption; (e) obtain customer
testimonials; (f) accurately predict growth assumptions; (g)
realize anticipated revenues; (h) incur expected levels of
operating expenses; or (i) increase the number of high-risk
patients at customer facilities; (ii) failure of early data to
predict eventual outcomes; (iii) failure to make or obtain
anticipated FDA filings or clearances within expected time frames
or at all; or (iv) the factors discussed under Item 1A. "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2019, filed with the U.S. Securities and
Exchange Commission, and other filings the Company makes with the
SEC from time to time. These and other important factors
could cause actual results to differ materially from those
indicated by the forward-looking statements made in this press
release. Any such forward-looking statements represent management's
estimates as of the date of this press release. While the Company
may elect to update such forward-looking statements at some point
in the future, unless required by law, it disclaims any obligation
to do so, even if subsequent events cause its views to change.
Thus, no one should assume that the Company’s silence over time
means that actual events are bearing out as expressed or implied in
such forward-looking statements. These forward-looking
statements should not be relied upon as representing the Company's
views as of any date subsequent to the date of this press
release.
Media Contact: Gina Kent, Vault
Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Philip Trip Taylor, Gilmartin
Group philip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024